Vanguard Asset Management’s Inhibrx INBX Stock Holding History

Vanguard Asset Management’s Portfolio INBX Stock Details INBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$455K	Hold	4,799	–	–	﹤0.01%	2220
2026 Q1	$323K	Buy	+4,799	New	+$356K	﹤0.01%	2278

Other funds holding INBX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $27.9B AUM 51.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Vanguard Asset Management's INBX Position: Q2 2026 in Review

Vanguard Asset Management held its Inhibrx (INBX) position steady in Q2 2026 at 4,799 shares worth $455K. The position accounts for ﹤0.01% of the portfolio, ranked #2220.

Vanguard Asset Management first reported a position in INBX in Q1 2026 and has held it in 2 quarters since. 148 funds tracked by Wall St. Rank hold INBX as of Q2 2026.

Vanguard Asset Management held 4,799 shares of Inhibrx worth $455K as of Q2 2026.
Vanguard Asset Management left its Inhibrx share count unchanged in Q2 2026.
Inhibrx made up ﹤0.01% of Vanguard Asset Management's portfolio in Q2 2026, its #2220 holding.
Vanguard Asset Management first reported a position in Inhibrx in Q1 2026 and has held it in 2 quarters since.
148 funds tracked by Wall St. Rank held Inhibrx as of Q2 2026.

Based on Vanguard Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.